{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:10:17Z","timestamp":1793823017628,"version":"4.6.1"},"reference-count":18,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Int Assoc Provid AIDS Care"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:p>Despite progress in human immunodeficiency virus (HIV) prevention, global targets remain unmet, with over 1.3 million new infections annually\u2014driven by adherence challenges, stigma, and daily pill fatigue linked to oral pre-exposure prophylaxis (PrEP). Lenacapavir, a long-acting injectable capsid inhibitor approved by the FDA in June 2025, offers transformative twice-yearly subcutaneous dosing with sustained efficacy and minimal drug interactions. PURPOSE 1 and 2 trials demonstrated near-complete protection across cisgender women, men who have sex with men, transgender individuals, and adolescents, highlighting its potential to overcome barriers to PrEP uptake. Its high acceptability, infrequent dosing, and pharmacologic durability make it ideal for individuals facing stigma, mobility constraints, or limited healthcare access. WHO's endorsement marks a pivotal milestone, but real-world implementation must address cold-chain logistics, cost, provider training, and systemic inequities. Integrating lenacapavir through decentralized delivery models, differentiated care, and inclusive national guidelines will be key to equitable access, decreasing gaps and advancing epidemic control.<\/jats:p>","DOI":"10.1177\/23259582251390622","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T16:35:27Z","timestamp":1762878927000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Twice-Yearly Injectable Pre-Exposure Prophylaxis With Lenacapavir: Redefining Adherence and Access in the Global Fight Against HIV"],"prefix":"10.1177","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9045-0683","authenticated-orcid":false,"given":"Santosh","family":"Sah","sequence":"first","affiliation":[{"name":"Dow University of Health Sciences (DUHS)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1751-9304","authenticated-orcid":false,"given":"Ureeba","family":"Iqbal","sequence":"additional","affiliation":[{"name":"Dow University of Health Sciences (DUHS)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trilok","family":"Mishra","sequence":"additional","affiliation":[{"name":"Dow University of Health Sciences (DUHS)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najeeb","family":"Ullah","sequence":"additional","affiliation":[{"name":"Dow University of Health Sciences (DUHS)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5229-3448","authenticated-orcid":false,"given":"Tularam","family":"Yadav","sequence":"additional","affiliation":[{"name":"Primary Healthcare Centre (PHCC) Jhorahat"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"HIV data and statistics World Health Organization Global HIV Programme. Accessed 23 July 2025."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101016"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506110"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3463-4"},{"key":"e_1_3_3_6_2","unstructured":"Major new policy updates announced at the IAS 2025 conference; WHO recommends injectable lenacapavir for HIV prevention WHO recommends injectable lenacapavir for HIV prevention. Accessed 23 July 2025."},{"key":"e_1_3_3_7_2","unstructured":"Yeztugo-Lenacapavir-Is-Now-the-First-and-Only-FDA-Approved-HIV-Prevention-Option-Offering-6-Months-of-Protection. Yeztugo Lenacapavir Is Now the First and Only FDA Approved HIV Prevention Option Offering 6 Months of Protection. Accessed 24 July 2025."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2443-1"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01786-0"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02057-20"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.117125"},{"key":"e_1_3_3_12_2","unstructured":"Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis World Health Organization. https:\/\/iris.who.int\/bitstream\/handle\/10665\/381892\/9789240111608-eng.pdf?sequence=1. Accessed 25 July 2025."},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407001"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411858"},{"key":"e_1_3_3_15_2","unstructured":"Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo\u00ae) for HIV Prevention at IAS 2025. https:\/\/www.gilead.com\/news\/news-details\/2025\/gilead-presents-new-data-on-twice-yearly-lenacapavir-yeztugo-for-hiv-prevention-at-ias-2025. Accessed 25 July 2025."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/v16091368"},{"key":"e_1_3_3_17_2","unstructured":"UNAIDS welcomes new WHO guidelines on Lenacapavir. https:\/\/www.unaids.org\/en\/resources\/presscentre\/pressreleaseandstatementarchive\/2025\/july\/20250714_PS_WHO_Lenacapavir_Guidelines. Accessed 25 July 2025."},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000159"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.3390\/tropicalmed7080154"}],"container-title":["Journal of the International Association of Providers of AIDS Care (JIAPAC)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23259582251390622","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/23259582251390622","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23259582251390622","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:50:46Z","timestamp":1777503046000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/23259582251390622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":18,"alternative-id":["10.1177\/23259582251390622"],"URL":"https:\/\/doi.org\/10.1177\/23259582251390622","relation":{},"ISSN":["2325-9582","2325-9582"],"issn-type":[{"value":"2325-9582","type":"print"},{"value":"2325-9582","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"article-number":"23259582251390622"}}